Novartis Intrinsic Value
Novartis (NOVARTIND) median intrinsic value is ₹783.33 from 9 valuation models (range ₹492–₹1363), vs current price ₹1641.20 — -52.3% downside (Trading Above Calculated Value), margin of safety -100.0%. Read Novartis dividend payments for the complete payout history and dividend yield track record.
NOVARTIND Valuation Methods Summary — DCF, Graham Number & P/E
Novartis intrinsic value across 9 models vs current price ₹1641.20 — upside/downside and value range per method. For current market price and key ratios, visit NOVARTIND screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹830.28 | ₹664.22 - ₹996.34 | -49.4% | EPS: ₹37.74, Sector P/E: 22x |
| Book Value Method | asset | ₹1363.33 | ₹1227.00 - ₹1499.66 | -16.9% | Book Value/Share: ₹681.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹590.00 | ₹531.00 - ₹649.00 | -64.1% | Revenue/Share: ₹295.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹783.33 | ₹705.00 - ₹861.66 | -52.3% | EBITDA: ₹94.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹848.96 | ₹679.17 - ₹1018.75 | -48.3% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹492.36 | ₹443.12 - ₹541.60 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹552.20 | ₹496.98 - ₹607.42 | -66.4% | Revenue Growth: -4.9%, Adj P/E: 14.6x |
| ROE Based Valuation | profitability | ₹950.00 | ₹855.00 - ₹1045.00 | -42.1% | ROE: 11.6%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹760.81 | ₹684.73 - ₹836.89 | -53.6% | EPS: ₹37.74, BVPS: ₹681.67 |
NOVARTIND Intrinsic Value vs Market Price — All Valuation Models
Novartis fair value range ₹492–₹1363 vs current market price ₹1641.20 across 9 valuation models. Analyse Novartis ownership pattern to track promoter, FII and institutional holdings.
NOVARTIND Intrinsic Value Analysis — Undervalued or Overvalued?
Novartis median intrinsic value ₹783.33, current price ₹1641.20 — Trading Above Calculated Value by 52.3%, margin of safety -100.0%.
What is the intrinsic value of NOVARTIND?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Novartis (NOVARTIND) is ₹783.33 (median value). With the current market price of ₹1641.20, this represents a -52.3% variance from our estimated fair value.
The valuation range spans from ₹492.36 to ₹1363.33, indicating ₹492.36 - ₹1363.33.
Is NOVARTIND undervalued or overvalued?
Based on our multi-method analysis, Novartis (NOVARTIND) appears to be trading above calculated value by approximately 52.3%.
NOVARTIND Financial Health — Key Ratios vs Industry Benchmarks
Novartis financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 48.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 11.6% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.36x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
NOVARTIND Cash Flow Quality — Operating & Free Cash Flow
Novartis operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹75 Cr | ₹74 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹113 Cr | ₹113 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹45 Cr | ₹-32 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹39 Cr | ₹39 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-69 Cr | ₹-69 Cr | Negative Cash Flow | 3/10 |